2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1677 FLT3-ITD length predicts FLT3 dependency and differential transcriptomic profiles in AML

Asmita Shukla, MD, Jeff Justin Aguilar, MD, MBA2, Vikram Dhillon, DO, MBA3, Sandhya Dhiman4, Dakshin Padmanabhan, MD5, Sikander Chohan, MD6, Yazan F. Madanat, MD7, Eno-obong Blessing Udoh, BS8, Jaroslaw P. Maciejewski, MD, PhD, FACP9, Hunter Dlugas, MS10, Yang Shi, PhD11, Jay Yang, MD12, Julie Boerner, PhD13, Suresh Kumar Balasubramanian, MD14
1 Karmanos Cancer Institute, Detroit, Michigan, United States
2 DMC Sinai Grace, Detroit, Michigan, United States
3 Karmanos Cancer Institute, Detroit, Michigan, United States
4 Karmanos Cancer Institute, Detroit, Michigan, United States
5 Karmanos Cancer Institute, Detroit, Michigan, United States
6 Wayne State University, Detroit, Michigan, United States
7 UT Southwestern Medical Center, Dallas, Texas, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Karmanos Cancer Institute, Detroit, Michigan, United States
11 Karmanos Cancer Institute, Detroit, Michigan, United States
12 Karmanos Cancer Institute, Detroit, Michigan, United States
13 Karmanos Cancer Institute, Detroit, Michigan, United States
14 Karmanos Cancer Institute, Detroit, Michigan, United States

Introduction
FLT3-ITD is an adverse prognostic driver in AML. Our previous work identified ITD length as a clinically relevant feature of FLT3-ITD AML. Intriguingly, whether long ITDs represent a predominantly FLT3-driven disease has not been mechanistically explored. We therefore performed ex vivo FLT3 inhibitor (FLT3i) sensitivity testing together with bulk RNA sequencing to compare the biological and transcriptomic characteristics of short-ITD (s-ITD) and long-ITD (l-ITD) AML models.

Methods
We identified 1,572 records from KCI, CCF, and UTSW (2016-2025), yielding 172 FLT3 mutated patients, 147 FLT3-ITD, and 90 with known ITD length to study their clinical correlation. Targeted NGS assessed FLT3 mutation type, ITD length, and co-mutations. ITD length was classified as short (<70bp) or long (≥70bp), with chi-square for categorical variables and Kaplan-Meier for OS/RFS. Ex-vivo FLT3i sensitivity was assessed in s-ITD (MV4-11, 30bp; MOLM-13, 21bp) and l-ITD (PL-21, 126bp) cell lines via CellTiter-Glo assays with gilteritinib/quizartinib (IC50). Bulk RNA sequencing (n=3 s-ITD vs n=3 l-ITD) characterized transcriptional programs via DESeq2 DE, GO/KEGG/Reactome/DO enrichment, and GSEA.

Results
Among 90 patients with FLT3-ITD AML, 64 (71%) had s-ITDs (<70 bp) and 26 (29%) l-ITDs (≥70 bp). Baseline characteristics were comparable between groups, including median age (63 years for both; p=NS); gender (male: 30/64, 47% vs 15/26, 58%; p=NS); complex karyotype (1/64, 2% vs 2/26, 8%; p=NS); transplant (34/64, 53% vs 8/26, 31%; p=NS); FLT3 inhibitor exposure (45/64, 70% vs. 22/26, 85%; p=NS) and relapse rate (34/64, 53% vs. 13/26, 50%; p=NS). Co-mutational patterns differed by ITD length: at diagnosis, s-ITDs were enriched for TET2 (13/64, 20% vs. 2/26, 8%), RUNX1 (4/64, 6% vs. 0), and SRSF2 (4/64, 6% vs. 0), whereas DNMT3A was more frequent in l-ITDs (9/26, 35% vs. 19/64, 29%); at relapse, TET2 became enriched in l-ITDs (2/13, 15% vs. 2/34, 6%), while RUNX1, TP53, PTPN11, and RAD21 remained confined to s-ITDs. Consistent with our prior report, s-ITDs were associated with inferior median OS (13.4 vs. 48.0 months; p=0.0002) and RFS (8.4 vs. 63.9 months; p=0.0017) compared with l-ITDs.

Ex vivo drug testing with FLT3i showed s-ITD cell lines to be more sensitive than l-ITD (gilteritinib IC50: 4.5 nM for MV4-11 and 16 nM for MOLM-13 at 48 h vs 105 nM for PL-21 at 72 h; quizartinib IC50: 1.1 nM and 2 nM vs. 800 nM). Since s-ITD required less drug exposure than l-ITD in viability assays, we wanted to explore additional drivers of bad outcomes in s-ITD vs l-ITD AML. Hence, we did transcriptomic profiling of 6 primary patient derived, CD-34 enriched AML samples (3 s-ITD, 3 l-ITD) to characterize disease driving genomic signatures.

We identified 564 differentially expressed genes (DEG), 146↑ and 418↓ in s-ITDs. DEGs segregated by ITD length with s-ITD showing coordinated upregulation of a HOXB developmental program (HOXB5, HOXB6, HOXB8, HOXB-AS3) and PRDM16, with enrichment of chromatin remodeling (ES=0.42, FDR=0.037) and autophagy/lysosomal pathways. Conversely, s-ITDs showed marked downregulation of adaptive immune response (52 genes↓), T-cell receptor signaling, PD-1/PD-L1 checkpoint, Th1/Th2 differentiation, cytokine signaling, oxidative phosphorylation, and ribosomal translation, relative to l-ITDs. Protein-protein interaction analysis resolved two modules: a HOXB-centered developmental network corresponding to genes upregulated in s-ITDs and a cytotoxic immune/NK-cell network corresponding to genes enriched in l-ITDs, with FLT3 localizing within the immune interaction module. 

Conclusion
Together, these findings demonstrate that FLT3-ITD length defines biologically distinct AML subgroups that help explain the survival disparity between s-ITD and l-ITD driven AML. l-ITD's immune-engaged, metabolically active program may support immune surveillance, while s-ITD's HOX-driven differentiation block, chromatin remodeling, and autophagy signature may favor leukemic persistence. While ex vivo drug testing demonstrated variable but robust sensitivity based on ITD length, differential clinical outcomes within the same subtype of FLT3-ITD AML may reflect distinct underlying biological processes, as predicted by ITD length itself. L-ITDs were associated with superior outcomes and s-ITDs with inferior outcomes potentially reflecting greater FLT3 dependence in l-ITD AML and alternative leukemogenic drivers in sITD.

Asmita Shukla, MD: No relevant conflicts of interest to declare.